Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.

<h4>Background</h4>Esophageal cancer is a highly malignant cancer with a very poor prognosis. For resectable esophageal cancer, neoadjuvant treatment could improve the prognosis of esophageal cancer. However, current clinical neoadjuvant treatment options for esophageal cancer are still...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Guocan Yu, Wenfeng Yu, Xudong Xu, Bo Ye, Liwei Yao
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0f234c56c733447bb46ce808453644be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0f234c56c733447bb46ce808453644be
record_format	dspace
spelling	oai:doaj.org-article:0f234c56c733447bb46ce808453644be2021-12-02T20:07:14ZNeoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.1932-620310.1371/journal.pone.0252829https://doaj.org/article/0f234c56c733447bb46ce808453644be2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0252829https://doaj.org/toc/1932-6203<h4>Background</h4>Esophageal cancer is a highly malignant cancer with a very poor prognosis. For resectable esophageal cancer, neoadjuvant treatment could improve the prognosis of esophageal cancer. However, current clinical neoadjuvant treatment options for esophageal cancer are still limited. The application of immunotherapy is a potentially beneficial new neoadjuvant treatment option for esophageal cancer. The objective of this meta-analysis is to evaluate the efficacy and safety of immunotherapy for the neoadjuvant treatment of esophageal cancer.<h4>Methods</h4>We will search Wanfang Database, SinoMed, China National Knowledge Infrastructure, Embase, Web of Science, Pubmed, and Cochrane Library for relevant articles published before July, 2021. We will also search the unpublished clinical trials of neoadjuvant immunotherapy in esophageal cancer in preprint website (such as bioRXiv and medRxiv) up to July, 2021. We will perform a meta-analysis to evaluate the efficacy and safety of neoadjuvant immunotherapy for resectable esophageal cancer. Randomized controlled trials (RCTs) will be included in this study. The risk of bias will be evaluated for each included study using the Cochrane Handbook for Systematic Reviews of Interventions. We will use RevMan 5.3 software for statistical analysis of the data.<h4>Results</h4>The results of this study will provide evidence of immunotherapy using as neoadjuvant treatment for esophageal cancer. This meta-analysis will be submitted to a peer-reviewed journal seeking for publication.<h4>Conclusion</h4>The results of this study will provide a reliable basis for clinicians and patients to formulate the best pre-surgical treatment plan for resectable esophageal cancer.<h4>Systematic review registration</h4>INPLASY202120026.Guocan YuWenfeng YuXudong XuBo YeLiwei YaoPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 6, p e0252829 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Guocan Yu Wenfeng Yu Xudong Xu Bo Ye Liwei Yao Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.
description	<h4>Background</h4>Esophageal cancer is a highly malignant cancer with a very poor prognosis. For resectable esophageal cancer, neoadjuvant treatment could improve the prognosis of esophageal cancer. However, current clinical neoadjuvant treatment options for esophageal cancer are still limited. The application of immunotherapy is a potentially beneficial new neoadjuvant treatment option for esophageal cancer. The objective of this meta-analysis is to evaluate the efficacy and safety of immunotherapy for the neoadjuvant treatment of esophageal cancer.<h4>Methods</h4>We will search Wanfang Database, SinoMed, China National Knowledge Infrastructure, Embase, Web of Science, Pubmed, and Cochrane Library for relevant articles published before July, 2021. We will also search the unpublished clinical trials of neoadjuvant immunotherapy in esophageal cancer in preprint website (such as bioRXiv and medRxiv) up to July, 2021. We will perform a meta-analysis to evaluate the efficacy and safety of neoadjuvant immunotherapy for resectable esophageal cancer. Randomized controlled trials (RCTs) will be included in this study. The risk of bias will be evaluated for each included study using the Cochrane Handbook for Systematic Reviews of Interventions. We will use RevMan 5.3 software for statistical analysis of the data.<h4>Results</h4>The results of this study will provide evidence of immunotherapy using as neoadjuvant treatment for esophageal cancer. This meta-analysis will be submitted to a peer-reviewed journal seeking for publication.<h4>Conclusion</h4>The results of this study will provide a reliable basis for clinicians and patients to formulate the best pre-surgical treatment plan for resectable esophageal cancer.<h4>Systematic review registration</h4>INPLASY202120026.
format	article
author	Guocan Yu Wenfeng Yu Xudong Xu Bo Ye Liwei Yao
author_facet	Guocan Yu Wenfeng Yu Xudong Xu Bo Ye Liwei Yao
author_sort	Guocan Yu
title	Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.
title_short	Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.
title_full	Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.
title_fullStr	Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.
title_full_unstemmed	Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.
title_sort	neoadjuvant immunotherapy for resectable esophageal cancer: a protocol of meta-analysis.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/0f234c56c733447bb46ce808453644be
work_keys_str_mv	AT guocanyu neoadjuvantimmunotherapyforresectableesophagealcanceraprotocolofmetaanalysis AT wenfengyu neoadjuvantimmunotherapyforresectableesophagealcanceraprotocolofmetaanalysis AT xudongxu neoadjuvantimmunotherapyforresectableesophagealcanceraprotocolofmetaanalysis AT boye neoadjuvantimmunotherapyforresectableesophagealcanceraprotocolofmetaanalysis AT liweiyao neoadjuvantimmunotherapyforresectableesophagealcanceraprotocolofmetaanalysis
_version_	1718375284080640000

Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.

Ejemplares similares